Publication year | Study | Country | Age of patient Mean (range or standard derivation) | Cut-off value by PSQ | CpGs | Sample source | No. patientsa | Disease status | Treatment experience | Score in NOS |
---|---|---|---|---|---|---|---|---|---|---|
2015 | Dae Cheol Kim | Korea | 51.4 (26.4–87.2) | 9 % | 5 CpGs | FFPE | 104 | Newly diagnosed GMB | No all patients treated with TMZ | 5 |
2015 | Robert W. Rapkinsb | Australia | 58.3 (25.0–85.0) | 9 % | 5 CpGs | FFPE | 303 | Newly diagnosed GMB | Surgery + radiotherapy + TMZ+ adjuvant TMZ | 6 |
2015 | Robert W. Rapkinsb | Australia | 57.8 (22.3–84.3) | 9 % | 5 CpGs | FFPE | 303 | Newly diagnosed GMB | Surgery + radiotherapy + TMZ+ adjuvant TMZ | 5 |
2014 | Veronique Quillien | France | 58 (21.0–73.0) | 9 % | 16 CpGs | FFPE | 89 | Newly diagnosed GMB | Stupp protocol | 5 |
2014 | Vincent Peter Collins | UK | 53 (41–60) | 10 % | 16 CpGs | FFPE | 275 | Recurrent high-grade GMB | PCV OR two TMZ schedules | 5 |
2014 | Dong Shen | China | 56 (35–71) | 10 % | 12 CpGs | FFPE | 128 | Recurrent high-grade GMB | Surgery + radiotherapy + TMZ+ adjuvant TMZ | 5 |
2012 | Guido Reifenberge | Germany | 74.1 (70.0–86.6) | 8 % | 5 CpGs | Frozen sample | 85 | Newly diagnosed GMB | Treated with alkylating agents | 5 |
2012 | Veronique Quillien | France | 57.5 (21.0–73.0) | 8 % | 5 CpGs | FFPE and frozen sample | 99 | Newly diagnosed GMB | Standard care treatment | 5 |
2011 | Miyuki Uno | Brazil | 50.2 (14.6) | 10 % | 5 CpGs | Frozen sample | 29 | Newly diagnosed GMB | Adjuvant radiotherapy and/or chemotherapy (carmustine) | 5 |
2011 | Shani Mulholland | Sweden | NA | 10 % | 16 CpGs | Frozen sample | 362 | GMB | Surgery + adjuvant treatment (no TMZ) | 5 |
2009 | J Dunn | UK | 55 (18–68) | 10 % | 12 CpGs | FFPE or frozen sample | 108 | Newly diagnosed GMB | Surgery + radiotherapy + TMZ+ adjuvant TMZ | 5 |